• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Renz Justin A

    3/19/26 4:15:55 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Renz Justin A

    (Last)(First)(Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    101 FEDERAL STREET

    (Street)
    BOSTON MASSACHUSETTS 02110

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    CFO
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/18/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (right to buy)$9.55(1)03/18/2026A300,000 (2)03/17/2036Common Stock300,000$0300,000D
    Explanation of Responses:
    1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026.
    2. Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
    Remarks:
    /s/ Brian Keane, Attorney-in-Fact for Justin Renz03/19/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ZVRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    3/16/2026$23.00Buy
    BTIG Research
    7/2/2025$26.00Buy
    H.C. Wainwright
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    More analyst ratings

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the "Inducement Awards") to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment o

    5/29/26 4:30:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

    BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. About Zevra Therapeutics, Inc. Zevra T

    5/12/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports First Quarter 2026 Financial Results and Corporate Update

    Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026, at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026. "We made meaningful progress across the business in the first quarter, led by continued performance for MIPLYFFA, underscoring

    5/6/26 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    SEC Filings

    View All

    SEC Form 144 filed by Zevra Therapeutics Inc.

    144 - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    5/11/26 4:34:12 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Zevra Therapeutics Inc.

    10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    5/6/26 5:14:17 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    5/6/26 4:05:48 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, Finance & Corp Controller Sangiovanni Timothy J.

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    5/29/26 4:16:13 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal & Compliance Thompson Rahsaan sold $20,272 worth of shares (1,794 units at $11.30) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 48,125 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    5/13/26 4:32:07 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bode John B

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    3/26/26 8:27:07 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Favorito Tamara A bought $24,718 worth of shares (3,175 units at $7.79), increasing direct ownership by 442% to 3,894 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/16/25 4:15:37 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shih Alvin bought $157,800 worth of shares (20,000 units at $7.89) (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/15/25 4:07:29 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bode John B bought $45,825 worth of shares (5,000 units at $9.16), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    8/20/25 4:38:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Zevra Therapeutics with a new price target

    BTIG Research initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $23.00

    3/16/26 8:43:46 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00

    7/2/25 7:59:19 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

    1/8/25 8:49:26 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Financials

    Live finance-specific insights

    View All

    Zevra Reports First Quarter 2026 Financial Results and Corporate Update

    Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026, at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026. "We made meaningful progress across the business in the first quarter, led by continued performance for MIPLYFFA, underscoring

    5/6/26 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call

    BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter on Wednesday, May 6, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800) 579-2543 (United States)+1 (78

    4/22/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted  Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended December 31, 2025. "MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, a

    3/9/26 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/12/24 5:59:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/4/24 2:15:20 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

    CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Mr. Renz brings more than 25 years of financial leadership experience in the biopharmaceutical industry, including extensive expertise in capital markets, strategic transactions, and commercial-stage operations. "Justin is a highly accomplished financial executive with a strong track record of driving growth and creating shareholder value across multiple biopharmaceutical organizat

    3/5/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

    SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). "As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "We are thrilled to welcome Mr. Clifton as Chief Financial Officer. He brings extensive public company, global finance, and operations leadership

    2/24/26 3:42:26 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

    CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture, as her expertise will support our continued execution of strategy and our commitment to delivering durable, sustained value for shareholders," said Tamara A. Favorito, Zevra's Chair of the Board. "We sincerely appreciate Wendy's

    12/2/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care